# Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Canonical URL: https://biopharmsignal.com/news/XERS/xeris-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-713b1411
Ticker: XERS
Company: Xeris Pharmaceuticals
Source: Xeris Pharmaceuticals
Published: 2026-07-02 20:05 EST
Original Source URL: https://xerispharma.com/news-releases/news-release-details/xeris-announces-inducement-grants-under-nasdaq-listing-rule-3
## Summary

CHICAGO --(BUSINESS WIRE)--Jul. 2, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the

## Article Body
CHICAGO --(BUSINESS WIRE)--Jul. 2, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the
## Recent Company News
- 2026-07-02 20:05 EST — [CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)](https://biopharmsignal.com/news/XERS/correcting-and-replacing-xeris-announces-inducement-grants-under-nasdaq-listing--0c3e5deb) — Source: Xeris Pharmaceuticals
- 2026-07-02 20:05 EST — [Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)](https://biopharmsignal.com/news/XERS/xeris-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-713b1411) — Source: Xeris Pharmaceuticals
- 2026-06-30 11:00 EST — [Xeris Announces Updates to Its Board of Directors](https://biopharmsignal.com/news/XERS/xeris-announces-updates-to-its-board-of-directors-f32772e5) — Source: Xeris Pharmaceuticals
- 2026-06-25 13:46 EST — [Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®](https://biopharmsignal.com/news/XERS/xeris-biopharma-announces-notice-of-allowance-from-u-s-patent-and-trademark-office-for-new-patent-covering-keveyisr) — Source: Xeris Pharmaceuticals
- 2026-06-25 13:46 EST — [Xeris Biopharma Announces Private Exchange of Convertible Notes](https://biopharmsignal.com/news/XERS/xeris-biopharma-announces-private-exchange-of-convertible-notes) — Source: Xeris Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)